RxDoctor Payments Data

Karla Avila, MD

Internal Medicine · San Antonio, TXNPI 1124656442

Payments from drug & device makers

$2,029in general payments, 2019–2025

Across 84 payments — averaging $24.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$628
  • Boston Scientific$279
  • Pfizer$143
  • Cvrx, Inc.$132
  • Lilly USA, LLC$114
  • Merck$112
  • plus $621 from 15 others

What the payments were for

  • Food & beverage$2,029100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,029 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$100,918
Medicare patients
188
Services billed
1,320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$30,006
MounjaroTirzepatide25$27,104
JardianceEmpagliflozin21$23,555
RybelsusSemaglutide11$20,864
EliquisApixaban14$10,928
MyrbetriqMirabegron16$9,882
Levothyroxine Sodium117$1,423
Rosuvastatin Calcium98$1,298
Albuterol Sulfate HfaAlbuterol Sulfate35$1,101
Atorvastatin Calcium116$953
SynthroidLevothyroxine Sodium16$910
Metoprolol Succinate37$825
Ezetimibe40$800
Gabapentin60$737
Losartan Potassium67$722

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$628$50,87035 claims
Lilly USA, LLCMounjaro$114$27,10425 claims
Boehringer IngelheimJardiance$16$23,55521 claims
PfizerEliquis$143$10,92814 claims
AbbVieSynthroid$70$91016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →